ClinicalTrials.gg
CompletedNCT05537142Updated Jan 14, 2025

A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment

A Phase 1 interventional study of BV100 in Healthy Participants, sponsored by BioVersys AG. Completed at 1 site in Hungary. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by BioVersys AG · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To investigate the pharmacokinetics (PK) of rifabutin in subjects with hepatic impairment after single intravenous (IV) infusion of BV100

Read the detailed description

To investigate the pharmacokinetics (PK) of rifabutin and excipient in subjects with hepatic impairment after single intravenous (IV) infusion of BV100. In addition to investigate the safety and tolerability of BV100 in subjects with hepatic impairment and to investigate the PK of 25-deacetyl-rifabutin metabolite in subjects with hepatic impairment after single intravenous (IV) infusion of BV100

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

BioVersys AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria will be:

All participants (Groups 1-4):

  1. Participants must provide written prior to any screening procedures being performed.
  2. Male and non-child bearing potential females between 18 and 75 years of age, inclusive
  3. Women of non- is defined as women who are physiologically and/or anatomically incapable of becoming pregnant, as now further described:

    • They are as evidenced by 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms).
    • They have had bilateral surgical oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks prior. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment she is considered not of childbearing potential.
  4. Participants must weigh at least 50.0 kg and must have a within the range of 18.0 to 38.0 kg/m2, inclusive, for healthy participants at Screening. For hepatic impairment participants without overt ascites, the BMI should be within the range of 18 to 40 kg/m2. For hepatic impairment participants with overt ascites, the BMI should be within the range of 18 to 45 kg/m2
  5. Participant is able to read, speak, and understand the local language, to understand and comply with the requirements of the study.
  6. Must be a non-smoker or agree to smoke no more than 10 cigarettes or equivalent nicotine containing products per day and are committed not to increase the consumption during the study period

    Additional inclusion criteria for healthy participants (Group 1):

  7. Each participant must match in age (+/- 10 years), gender, weight (+/- 20%), and smoking status to a participant in Groups 2, 3 and/or 4.
  8. Seated vital signs must be within the following ranges at Screening and Baseline:

    • Body temperature, 35.0 to 37.5°C, inclusive
    • Systolic blood pressure, 89 to 140 mmHg, inclusive
    • Diastolic blood pressure, 50 to 90 mmHg, inclusive
    • Pulse rate, 40 to 100 bpm, inclusive
  9. Healthy participants with no abnormalities as determined by past medical history, physical examination, vital signs, , and clinical laboratory test

    Additional inclusion criteria for mild, moderate and severe hepatic impairment participants (Groups 2-4):

  10. Participants with Clinical Assessment Score as calculated per the Child-Pugh classification.
  11. Seated vital signs must be within the following ranges at Screening and Baseline:

    • Body temperature, 35.0 to 37.5°C, inclusive
    • Systolic blood pressure, 89 to 160 mmHg, inclusive
    • Diastolic blood pressure, 50 to 100 mmHg, inclusive
    • Pulse rate, 40 to 100 bpm, inclusive
  12. Stable Child-Pugh status at Screening and Baseline visits
  13. Participants with impaired hepatic function and other stable medical disorders such as diabetes, hypertension, hyperlipidemia, hypothyroidism etc., are eligible, as long as they are considered appropriate for enrollment, as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at Screening and Baseline

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria will be:

All participants (Groups 1-4):

  1. or to the compound/compound class or being used in this study.
  2. Woman of , or pregnant or lactating females.
  3. Sexually active males unless they use a condom during intercourse for 8 weeks after BV100 intake and must not father a child in this 8 week period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. In addition, male participants must not donate sperm for 8 weeks after study drug intake.
  4. History or presence of abnormalities or a family history or presence of prolonged -interval syndrome.
  5. Abnormal ECG findings at Screening:

    • Clinically significant ST/T wave abnormalities as determined by the Investigator
    • Inability to determine the QT interval on ECG
    • Specific to hepatic impaired patients:

      o QTcF > 480 ms (males and females)

    • Specific to healthy control participants:

      • PR > 220 ms, QRS complex > 120 ms, QTcF > 450ms for males; QTcF > 470ms for females.
  6. Clinically significant cardiac conduction abnormality as determined by the Investigator
  7. History of clinically significant cardiovascular disease (e.g., congestive heart failure Class II-IV, atherosclerosis, labile hypertension or uncontrolled hypertension)
  8. History of psychiatric illness within the past 2 years that may interfere with the ability to comply with the protocol requirements.
  9. History of of any organ system, treated or untreated, within 3 years, regardless of whether there is recurrence or . Those with localized basal cell carcinoma of the skin, in-situ cervical cancer, or hepatocellular cancer treated with local ablative therapy more than 6 months ago may be enrolled.
  10. Recent (within the last 3 years of Screening) or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting palpitations).
  11. History of immunodeficiency diseases, including a positive test result.
  12. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the participant in case of participation in the study.
  13. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection or cholecystectomy (cholecystectomy allowed for severe participants only)
  14. History of, or clinical evidence of, pancreatic injury or pancreatitis within the preceding 1 month prior to dosing
  15. Evidence of urinary obstruction or difficulty in voiding at screening
  16. Use of investigational drugs (i.e., participation in any clinical investigation) within 4 weeks prior to dosing or longer if required by local regulation, or within 5 half-lives of the investigational agent taken prior to dosing (whichever is longer).
  17. Consumption of Seville oranges, grapefruit, grapefruit juices, grapefruit hybrids, pomelos, pomegranates, star fruit, or exotic fruits (as well as their juices) and cruciferous vegetables (such as Brussel sprouts, broccoli, cabbage, cauliflower) for 14 days prior to dosing until completion of the End of Study Visit. The juices (except for orange juice) and products containing these fruits must also be avoided.
  18. Administration of medications that prolong the QT interval within 14 days or 5 half-lives, whichever is longer, prior to dosing and throughout the study.
  19. Use of any against infectious diseases within 4 weeks of initiation of study treatment. Coronavirus disease (COVID-19) vaccines will be restricted within 2 weeks prior to dosing of study treatment until completion of the End of Study visit.
  20. Participants not willing to abstain from alcohol 48 hours prior to dosing, confirmed by alcohol breath test at baseline, and until after Study Completion evaluation.
  21. Participants with known ongoing alcohol and/or drug abuse within 1 month prior to Screening or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations. For participants with impaired hepatic function (groups 2-4), participation in the study may be allowed, if the positive drug screen is due to prescription drug use for a specific symptom such as insomnia or pain. Unhealthy alcohol use is defined as use more than 24g pure alcohol per day for male and 12 g for female (12 g equals to approximately 300 mL beer, 100 mL wine, or 25 mL spirits).
  22. Donation or loss of 500 mL or more of blood within 8 weeks prior to dosing.
  23. Potentially unreliable or vulnerable participants (e.g., person kept in detention) and those judged by the investigator to be unsuitable for the study.
  24. Participant has positive Coronavirus (SARS-CoV-2) rapid test and positive PCR test upon Check-in on Day-1.
  25. Participant who had severe course of COVID-19 (e.g., hospitalisation and/or extra-corporeal membrane oxygenation, mechanically ventilated) within 2 months prior to Screening.
  26. Acute or C infection at Screening or active infection requiring therapy that will not be completed before screening.

    Additional exclusion criteria for healthy participants (Group 1):

  27. Significant illness within the 2 weeks prior to dosing
  28. , AST, GGT, or ALP ≥ 1.2 OR total ≥ ULN OR any elevation ≥ ULN of more than one parameter among ALT, AST, GGT or ALP at Screening or Baseline.
  29. Participants known to have Gilbert´s syndrome.
  30. levels below ≤ LLN at Screening or Baseline (unless deemed not clinically significant by the investigator).
  31. count ≤ LLN at Screening or Baseline (unless deemed not clinically significant by the investigator).
  32. Presence of impaired renal function as indicated by serum creatinine > ULN or abnormal urinary constituents (e.g., albuminuria) at Screening.
  33. Chronic hepatitis B or infection.
  34. Intake of any prescription or non-prescription medication, dietary supplements, vitamins or herbal remedies within 2 weeks prior to the dosing of study treatment and within 4 weeks prior to dosing for treatment known to affect . Limited use of acetaminophen (up to 2g/day) is acceptable but must be documented in the Concomitant Medications/Significant non-drug therapies page of the electronic Case Report Forms (eCRF).

    Mild and moderate hepatic impairment participants (Groups 2-3):

  35. Participants with hepatic impairment with abnormal laboratory values for the following parameters at Screening or Baseline:

    • Hemoglobin \< 9 g/dL.
    • Platelet count \< 30 × 109/L.
    • White blood cell count \< 2.5 × 109/L.
    • Total bilirubin > 8 mg/dL.
    • Serum amylase > 5 × ULN with no abdominal symptoms (>2 x ULN with abdominal symptoms)
    • International standardized ratio () > 2.5.
    • Corrected serum calcium \< 8.6 or > 10.2 mg/dL.
  36. Severe complications of liver disease within the preceding 3 months prior to dosing.
  37. Hospitalisation due to liver disease within the preceding 1 month prior to dosing.
  38. Participant has received liver transplant at any time in the past and is on therapy.
  39. Participants requiring paracentesis more than every 3 weeks for the management of ascites are excluded. Participants who are receiving diuretics to manage ascites can be enrolled and will be assigned the score for the degree of ascites while on diuretic treatment. The diuretic dose must have been stable for 7 days prior to dosing.
  40. Transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting.
  41. Clinically significant abnormal findings in physical examination, ECG, or laboratory evaluations, not consistent with known clinical disease.
  42. Significant change or addition to routine medication (prescribed) within 1 month prior to dosing, except for changes to medication that require frequent dose adjustments, such as insulin, furosemide (Lasix), Aldactone or analgesia, which can be made within 14 days prior to dosing, as agreed between the investigator and BioVersys.
  43. Active Grade 3 or 4 hepatic encephalopathy within 1 month prior to dosing.
  44. Primary biliary cholangitis or biliary obstruction.
  45. History of gastrointestinal bleeding requiring hospitalisation within the past 3 months prior to Screening.
  46. Presence of moderate to severe impaired renal function as indicated by any or all of the following criteria:

    • \< 50 mL/min as calculated using the Cockcroft-Gault formula or \< 50 mL/min/1.73 m2 based on CK-EPI calculation.
    • Serum creatinine > 1.5 × ULN.
  47. Clinically significant abnormal findings in physical examination, ECG or laboratory evaluations, not consistent with known clinical disease
  48. Clinically significant illness within 2 weeks prior to dosing that may jeopardize safety of the study participant and/or alter the study results as judged by the investigator
  49. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled di-abetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with protocol
  50. Participants with hepatic impairment may continue to receive medications required to treat their current disease upon confirmation by BioVersys, with exception of moderate or strong CYP3A4 inducers or inhibitors within 4 weeks prior to dosing until completion of the End of Study Visit.

    Severe hepatic impairment participants (Group 4):

  51. Participants with hepatic impairment with abnormal laboratory values for the following parameters at Screening or Baseline:

    • Hemoglobin \< 8.5 g/dL.
    • Platelet count \< 30 × 109/L.
    • White blood cell count \< 2.5 × 109/L.
    • Total bilirubin > 8 mg/dL.
    • Serum amylase > 5 × ULN with no abdominal symptoms (>2 x ULN with ab-dominal symptoms).
    • International standardized ratio (INR) > 2.5.
  52. Severe complications of liver disease within the preceding 1 months prior to dosing.
  53. Participant has received liver transplant at any time in the past and is on immunosuppressant therapy.
  54. Participants requiring paracentesis more than every 3 weeks for the management of ascites are excluded. Participants who are receiving diuretics to manage ascites can be enrolled and will be assigned the Child-Pugh score for the degree of ascites while on diuretic treatment. The diuretic dose must have been stable for 7 days prior to dosing.
  55. Transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting.
  56. Clinically significant abnormal findings in physical examination, ECG, or laboratory evaluations, not consistent with known clinical disease.
  57. Significant change or addition to routine medication (prescribed) within 1 month prior to dosing, except for changes to medication that require frequent dose adjustments, such as insulin, furosemide (Lasix), Aldactone or analgesia, which can be made within 14 days prior to dosing, as agreed between the investigator and BioVersys.
  58. Presence of moderate to severe impaired renal function as indicated by any or all of the following criteria:

    • Creatinine clearance \< 50 mL/min as calculated using the Cockcroft-Gault formula or eGFR \< 50 mL/min/1.73 m2 based on CK-EPI calculation.
    • Serum creatinine > 1.5 × ULN.
  59. Active Grade 3 or 4 hepatic encephalopathy within 1 month prior to dosing.
  60. Primary biliary cholangitis or biliary obstruction.
  61. History of gastrointestinal bleeding requiring hospitalisation within the past 3 months prior to Screening.
  62. Clinically significant illness within 2 weeks prior to dosing that may jeopardize safety of the study participant and/or alter the study results as judged by the investigator
  63. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled di-abetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with protocol.
  64. Participants with hepatic impairment may continue to receive medications required to treat their current disease upon confirmation by BioVersys, with exception of moderate or strong CYP3A4 inducers or inhibitors within 4 weeks prior to dosing until completion of the End of Study Visit.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants with Normal hepatic Function

    Drug: BV100

  • Experimental
    Group 2

    Participants with mild hepatic impairment: Child-Pugh A (Score 5-6)

    Drug: BV100

  • Experimental
    Group 3

    Participants with moderate hepatic impairment: Child-Pugh B (Score 7-9)

    Drug: BV100

  • Experimental
    Group 4

    Participants with severe hepatic impairment: Child-Pugh C (Score 10-15)

    Drug: BV100

Interventions

  • DrugBV100

    Rifabutin for Infusion

06

What researchers measure

Primary outcomes

  1. To investigate the pharmacokinetics (PK) of rifabutin in participants with hepatic impairment

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 15 days

  2. To characterize the single dose pharmacokinetic profile of rifabutin

    Peak Plasma Concentration (Cmax)

    Time frame: 15 days

Secondary outcomes

  1. To investigate the safety and tolerability of single intravenous ascending doses of BV100 assessed by the nature, occurrence, and severity of treatment-emergent adverse events

    Safety and Tolerability

    Time frame: 31 Days

  2. To determine the plasma concentration of the main metabolite 25-O-Desacetyl-Rifabutin in plasma in participants with hepatic impairment

    Pharmacokinetics

    Time frame: 15 days

  3. To determine the plasma concentration of DMI in plasma in subjects with hepatic impairment

    Pharmacokinetics

    Time frame: 15 days

07

Study locations

1 site
  • CRU Hungary Kft., Early Phase Unit
    Kistarcsa, H-2143, Hungary
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jul 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2022
First posted
Sep 13, 2022
StartActual
Sep 2, 2022
Primary completionActual
Jul 30, 2024
CompletionActual
Oct 30, 2024
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05537142
Lead sponsor
BioVersys AG
Collaborators
Clinical Research Units Hungary
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Sep 2, 2022
Primary completion
Jul 30, 2024
Completion
Oct 30, 2024
Last update
Jan 14, 2025

Study contacts

Geza Lakner, MD
principal investigator · Clinical Research Units Hungary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BV100

Start the discussion